Key Points The key to the company's future is medical insurers adopting Galleri. The FDA looks likely to grant pre-market approval for Galleri following this week's vote. 10 stocks we like better than Grail › Grail 's (NASDAQ: GRAL) stock surged after a Food and Drug Administration (FDA) Advisory Committee voted favorably on the safety, benefit-risk profile, and effectiveness of its multi-cancer early detection test (MCED), Galleri. It marks a remarkable turnaround for the stock after a February crash following the release of top-line results from a landmark Galleri trial that revealed it had missed its primary endpoint. Here's why this recovery could continue. The investment case for Grail stock The Galleri test is already in use.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.